ライフサイエンスコーパス: platelet glycoprotein

1 nds for the scavenger receptor CD36, a major platelet glycoprotein.

2 ave further implications for the function of platelet glycoproteins.

3 adhesion molecule-1 (VCAM 1) P-selectin, and platelet glycoprotein-1balpha (GPIbalpha) in the thoraci

4 Cartilage intermediate layer protein and platelet glycoprotein 4 (CD36) were identified as having

5 in a multimerized form, which interacts with platelet glycoproteins and integrins, is a major factor

6 es of vascular damage by binding to specific platelet glycoproteins and to constituents of exposed co

7 platelet sialidase to cause desialylation of platelet glycoproteins, and accelerated platelet clearan

8 dial infarction (UA/NSTEMI) treated with the platelet glycoprotein (Gp IIb/IIIa) inhibitor tirofiban

9 a locus immediately adjacent to that of the platelet glycoprotein (GP) Ib b.

10 An absent platelet glycoprotein (GP) Ib-IX receptor results in the

11 We have reconstituted the platelet glycoprotein (GP) Ib-IX-mediated activation of

12 The interaction between platelet glycoprotein (GP) Ib-IX-V complex and von Wille

13 The platelet glycoprotein (GP) Ib-IX-V complex is the recept

14 The platelet glycoprotein (GP) Ib-IX-V complex mediates the

15 The interaction of the platelet glycoprotein (GP) Ib-IX-V complex with von Will

16 duced platelet aggregation by binding to the platelet glycoprotein (GP) Ib-IX-V complex.

17 imary hemostasis owing to the absence of the platelet glycoprotein (GP) Ib-IX-V membrane receptor.

18 Shear stress causes the platelet glycoprotein (Gp) Ib/IX/V to bind to von Willeb

19 raction between the amino-terminal domain of platelet glycoprotein (GP) Ibalpha and immobilized von W

20 We have identified platelet glycoprotein (GP) Ibalpha as a counterreceptor

21 tion between von Willebrand factor (VWF) and platelet glycoprotein (GP) Ibalpha.

22 erties regulating A1 domain interaction with platelet glycoprotein (GP) Ibalpha.

23 uced brain injury in response to blockade of platelet glycoprotein (GP) Ibalpha.

24 CD11b/CD18) on DCs as a counterreceptor for platelet glycoprotein (GP) Ibalpha.

25 n the alphaMI domain as the binding site for platelet glycoprotein (GP) Ibalpha.

26 ntegrin alpha(IIb)beta(3), also known as the platelet glycoprotein (GP) IIb-IIIa complex, mediates pl

27 erfusion, tirofiban, a specific inhibitor of platelet glycoprotein (GP) IIb-IIIa receptors (100 micro

28 Interactions between platelet glycoprotein (Gp) IIb/IIIa and plasma proteins

29 as done to determine whether eptifibatide, a platelet glycoprotein (GP) IIb/IIIa antagonist, prevents

30 Platelet glycoprotein (GP) IIb/IIIa antagonists are indi

31 Platelet glycoprotein (GP) IIb/IIIa antagonists prevent

32 Monoclonal anti-rabbit platelet glycoprotein (GP) IIb/IIIa antibody (AZ1) was a

33 thin PLNs of ITP, but not controls, abundant platelet glycoprotein (GP) IIb/IIIa autoantigens was fou

34 nd eptifibatide (5 microg/mL), which inhibit platelet glycoprotein (GP) IIb/IIIa but not Mac-1, did n

35 s have been made to evaluate the role of the platelet glycoprotein (GP) IIb/IIIa complex in platelet-

36 ion (PCI) using bivalirudin with provisional platelet glycoprotein (GP) IIb/IIIa inhibition with that

37 ed to receive a double-blind infusion of the platelet glycoprotein (GP) IIb/IIIa inhibitor eptifibati

38 a strategy of upstream use of small molecule platelet glycoprotein (GP) IIb/IIIa inhibitors for all a

39 es have shown a survival benefit with use of platelet glycoprotein (GP) IIb/IIIa inhibitors in diabet

40 I) less than 25 kg/m2 and those treated with platelet glycoprotein (GP) IIb/IIIa inhibitors, in whom

41 ry revascularization who received either the platelet glycoprotein (GP) IIb/IIIa receptor antagonist

42 The platelet glycoprotein (GP) IIb/IIIa receptor antagonist

43 Platelet glycoprotein (GP) IIb/IIIa receptor antagonists

44 Several platelet glycoprotein (GP) IIb/IIIa receptor antagonists

45 o-controlled randomized trials of parenteral platelet glycoprotein (GP) IIb/IIIa receptor antagonists

46 ribes the effects of tirofiban, a nonpeptide platelet glycoprotein (GP) IIb/IIIa receptor blocker, on

47 ents with ACS derive particular benefit from platelet glycoprotein (GP) IIb/IIIa receptor inhibition.

48 dogrel, low-molecular-weight heparin (LMWH), platelet glycoprotein (GP) IIb/IIIa receptor inhibitors,

49 The platelet glycoprotein (GP) IIb/IIIa receptor is importan

50 The platelet glycoprotein (GP) IIb/IIIa receptor is the fina

51 ent of a monoclonal antibody directed to the platelet glycoprotein (GP) IIb/IIIa receptor, is a poten

52 inhibitor-1 (PAI-1) [-675] 4G/5G, and three platelet glycoprotein (GP) receptor variants (GPIa C807T

53 Platelet glycoprotein (GP) VI is a 62-kDa membrane glyco

54 dies to fibrin cross-linking factor XIII and platelet glycoprotein (GP)-IIIa to identify fibrin-plate

55 a quantitative or qualitative defect in the platelet glycoprotein (GP)Ib/IX complex.

56 onoclonal antibody 7E3, directed against the platelet glycoprotein (GP)IIb/IIIa receptor, on the char

57 reveals high-affinity antibody (Ab) against platelet glycoprotein (GP)IIIa 49-66, which correlates i

58 In platelets, glycoprotein (GP)Ib-IX receptor complex has b

59 intravascular bacteria, a process involving platelet glycoprotein GPIb and bacterial opsonization wi

60 Immunofluorescence staining of platelet glycoprotein GPIbalpha and fibrin(ogen) reveale

61 The platelet glycoproteins (GPs) Ib, integrin alpha(2)beta(1

62 IIb)beta3 (glycoprotein IIb-IIIa) is a major platelet glycoprotein heterodimeric receptor that mediat

63 The platelet glycoprotein Ib (GpIb) complex is composed of f

64 hemostasis is mediated by interaction of the platelet glycoprotein Ib (GPIb) surface receptor and its

65 ediates platelet adhesion through binding to platelet glycoprotein Ib (GPIb).

66 ed by absorption with mouse antihuman CD42b [platelet glycoprotein Ib (GPIb)] mAb, had sizes and carg

67 Mutations in VWF or platelet glycoprotein Ib can either reduce or increase t

68 ntibody that inhibits binding of thrombin to platelet glycoprotein Ib inhibits secretory responses to

69 Platelet glycoprotein Ib, T-cell receptor, and integrins

70 rated that neither von Willebrand factor nor platelet glycoprotein Ib-alpha receptor (GPIb-alpha) is

71 induced by VWF binding to its receptor, the platelet glycoprotein Ib-IX (GPIb-IX), and p38 inhibitor

72 The platelet glycoprotein Ib-IX receptor binds surface-bound

73 nd factor (vWF)-dependent recruitment of the platelet glycoprotein Ib-IX receptor complex and collage

74 idge between subendothelial collagen and the platelet glycoprotein Ib-IX-V complex (GPIb).

75 The platelet glycoprotein Ib-IX-V complex (GPIb-IX-IV) is th

76 The platelet glycoprotein Ib-IX-V complex plays critical rol

77 The platelet glycoprotein Ib-IX-V complex plays crucial role

78 (b)alpha), the ligand binding subunit of the platelet glycoprotein Ib-IX-V complex, is sulfated on th

79 This process requires the binding of platelet glycoprotein Ib-IX-V to the A1 domain of VWF mo

80 pass (1) platelet rolling via interaction of platelet glycoprotein Ib-IX-V with endothelial-released

81 sease (PT-VWD) is a bleeding disorder of the platelet glycoprotein Ib-IX/von Willebrand factor (VWF)

82 for interaction with a peptide derived from platelet glycoprotein Ib.

83 A1 domain that mediates vWF interaction with platelet glycoprotein Ib.

84 upported platelet binding, which depended on platelet glycoprotein Ib.

85 ypes I and III but also decreased binding to platelet glycoproteins Ib and IIbIIIa.

86 activated in shear flow to bind collagen and platelet glycoprotein Iba.

87 Domains A1 and A3 bind to platelet glycoprotein Ibalpha (GPIbalpha) and collagen,

88 The adhesion was mediated by platelet glycoprotein Ibalpha (GPIbalpha) because the ad

89 We have determined the structure of platelet glycoprotein Ibalpha (GpIbalpha) bound to throm

90 h increase affinity of the VWF A1 domain and platelet glycoprotein Ibalpha (GPIbalpha) for one anothe

91 tion initiation site (Kozak sequence) of the platelet glycoprotein Ibalpha (GPIbalpha) gene was assoc

92 filamin A binding to the cytoplasmic tail of platelet glycoprotein Ibalpha (GpIbalpha) is regulated b

93 ypothesis that VWF may self-associate on the platelet glycoprotein Ibalpha (GpIbalpha) receptor under

94 in, corresponding to the binding site of the platelet glycoprotein Ibalpha (GPIbalpha) receptor, ther

95 von Willebrand factor binding region of the platelet glycoprotein Ibalpha (GPIbalpha) subunit.

96 Binding of platelet glycoprotein Ibalpha (GPIbalpha) to von Willebr

97 xosite I in alpha-thrombin (FIIa) binding to platelet glycoprotein Ibalpha (GPIbalpha), which could i

98 : the von Willebrand factor (VWF) binding to platelet glycoprotein Ibalpha (GPIbalpha).

99 ebrand factor (VWF) regulates the binding to platelet glycoprotein Ibalpha (GPIbalpha).

100 and mediates the adhesion of neutrophils to platelet glycoprotein Ibalpha (GPIbalpha).

101 isting of von Willebrand factor (substrate), platelet glycoprotein Ibalpha (receptor), and ADAMTS13 (

102 pe 2B has increased binding affinity between platelet glycoprotein Ibalpha and von Willebrand factor

103 These cells expressed alphaIIbbeta3 and platelet glycoprotein Ibalpha but were devoid of hematop

104 njury, suggesting that a major inhibition of platelet glycoprotein Ibalpha may be beneficial therapy.

105 single VWF A1A2A3 tridomain polypeptides by platelet glycoprotein Ibalpha or antibodies to measure t

106 has been suggested as a counter receptor to platelet glycoprotein Ibalpha that supports initial plat

107 s occurs through transient interactions with platelet glycoprotein Ibalpha via the VWF A1 domain whic

108 rmed on the 16-residue beta-switch region of platelet glycoprotein Ibalpha, for which crystal structu

109 not a strict requirement for VWF binding to platelet glycoprotein Ibalpha.

110 was described to require the VWF receptor on platelets (glycoprotein Ibalpha (GPIbalpha)), the VWF/GP

111 d binding, a primary interaction that allows platelets glycoprotein Ibalpha (GPIbalpha)-induced gener

112 The platelet glycoprotein IIb (alpha(IIb); CD41) constitutes

113 d from ITP patients, 2E7, specific for human platelet glycoprotein IIb heavy chain, and 5E5, specific

114 In contrast, epinephrine-induced platelet glycoprotein IIb-IIIa expression increased afte

115 The Platelet Glycoprotein IIb-IIIa in Unstable Angina: Recep

116 tes in the design of a novel class of potent platelet glycoprotein IIb-IIIa receptor (GPIIb-IIIa) ant

117 the vitronectin receptor) or alphaIIbbeta3 (platelet glycoprotein IIb-IIIa), and binding was blocked

118 inst platelet surface proteins, particularly platelet glycoprotein IIb/IIIa (alpha(IIb)beta(3)).

119 using a murine monoclonal antibody to human platelet glycoprotein IIB/IIIA (CD41) and immunomagnetic

120 The goal of this study was to test: 1) if platelet glycoprotein IIb/IIIa (GP IIb/IIIa) blockade wi

121 rrent guidelines recommend administration of platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors,

122 Parenteral administration of platelet glycoprotein IIb/IIIa (GP IIb/IIIa) receptor bl

123 Pharmacodynamic effects of the platelet glycoprotein IIb/IIIa antagonist eptifibatide h

124 lacebo-controlled trials testing intravenous platelet glycoprotein IIb/IIIa antagonists in the settin

125 new adjunctive agents and devices, including platelet glycoprotein IIb/IIIa antagonists, primary sten

126 tion (MI) when performed with or without the platelet glycoprotein IIb/IIIa antibody, abciximab.

127 However, the efficacy of stenting with platelet glycoprotein IIb/IIIa blockade has not yet been

128 stent deployment and the effect of abciximab platelet glycoprotein IIb/IIIa blockade to improve clini

129 Platelet glycoprotein IIb/IIIa blockade with abciximab (

130 Lotrafiban, an orally administered platelet glycoprotein IIb/IIIa blocker, induced a 33% in

131 been characterized as a potent and specific platelet glycoprotein IIb/IIIa complex (GPIIb/IIIa) anta

132 IIb/IIIa Inhibitor for STENTing (EPISTENT), Platelet glycoprotein IIb/IIIa in Unstable angina Recept

133 tcomes of 429 patients from 153 sites in the Platelet glycoprotein IIb/IIIa in unstable angina: Recep

134 elet aggregation in patients enrolled in the Platelet glycoprotein IIb/IIIa in Unstable angina: Recep

135 ional, randomized, placebo-controlled trial (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Recep

136 gment elevation ACS who were enrolled in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Recep

137 /IIIa receptor inhibitor eptifibatide in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Recep

138 e from the economic substudy of the PURSUIT (Platelet Glycoprotein IIB/IIIA In Unstable Angina: Recep

139 e and tPA for Occluded Arteries (GUSTO)-IIb, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Recep

140 ed Coronary Arteries (GUSTO) IIb, GUSTO-III, Platelet Glycoprotein IIb/IIIa in Unstable Angina: Recep

141 tential of combined fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition for improving

142 bosis-II (trial) (IMPACT-II), a trial of the platelet glycoprotein IIb/IIIa inhibitor eptifibatide.

143 rst in vivo study of combination intravenous platelet glycoprotein IIb/IIIa inhibitor therapy.

144 device, Angioguard, or double-blind use of a platelet glycoprotein IIb/IIIa inhibitor, abciximab, in

145 and pharmacodynamics of lotrafiban, an oral platelet glycoprotein IIb/IIIa inhibitor, as a secondary

146 in and neutrophil receptor CD11b/CD18, and a platelet glycoprotein IIb/IIIa inhibitor, were incubated

147 ere performed prior to the widespread use of platelet glycoprotein IIb/IIIa inhibitors and intracoron

148 Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to

149 ascularization, agents in the class known as platelet glycoprotein IIb/IIIa inhibitors have significa

150 combination with PTCA, coronary stenting and platelet glycoprotein IIb/IIIa inhibitors may further im

151 Although many believe that platelet glycoprotein IIb/IIIa inhibitors should be used

152 Stents were used in 12 trials, and platelet glycoprotein IIb/IIIa inhibitors were used in e

153 target microvascular dysfunction, including platelet glycoprotein IIb/IIIa inhibitors, and agents de

154 t implantation, concurrent administration of platelet glycoprotein IIb/IIIa inhibitors, and the exact

155 To date, the other platelet glycoprotein IIb/IIIa inhibitors, including Int

156 VUS imaging in the era before routine use of platelet glycoprotein IIb/IIIa inhibitors.

157 Platelet glycoprotein IIb/IIIa is a membrane receptor fo

158 Monoclonal antibody to platelet glycoprotein IIb/IIIa receptor (7E3) has been s

159 ught to determine the efficacy and safety of platelet glycoprotein IIb/IIIa receptor (GP IIb/IIIa) bl

160 ilin Therapy, PURSUIT) demonstrated that the platelet glycoprotein IIb/IIIa receptor antagonist eptif

161 ented a therapeutic benefit for abciximab, a platelet glycoprotein IIb/IIIa receptor antagonist, that

162 -aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists duri

163 Although gender differences in response to platelet glycoprotein IIb/IIIa receptor blockade have be

164 Previous work has suggested that platelet glycoprotein IIb/IIIa receptor blockade may con

165 We sought to determine the effects of platelet glycoprotein IIb/IIIa receptor blockade on adve

166 Platelet glycoprotein IIb/IIIa receptor blockade with ep

167 The use of platelet glycoprotein IIb/IIIa receptor blockers did not

168 Clinical benefit was seen even when platelet glycoprotein IIb/IIIa receptor blockers were ad

169 Inhibitors of the platelet glycoprotein IIb/IIIa receptor given intravenou

170 tly recommended drug regimens to inhibit the platelet glycoprotein IIb/IIIa receptor have distinct ph

171 afiban, an oral, selective antagonist of the platelet glycoprotein IIb/IIIa receptor in patients stab

172 tion, combination reperfusion therapy with a platelet glycoprotein IIb/IIIa receptor inhibitor (abcix

173 who were randomly assigned to placebo or the platelet glycoprotein IIb/IIIa receptor inhibitor eptifi

174 ve suggested that agents that antagonize the platelet glycoprotein IIb/IIIa receptor may reduce the i

175 ST-segment resolution with higher levels of platelet glycoprotein IIb/IIIa receptor occupancy after

176 eptifibatide may result in higher levels of platelet glycoprotein IIb/IIIa receptor occupancy in the

177 Platelet glycoprotein IIb/IIIa receptor occupancy was si

178 e coronary syndromes results in higher local platelet glycoprotein IIb/IIIa receptor occupancy, which

179 Thus, blockade of the platelet glycoprotein IIb/IIIa receptor reduces ischemic

180 Blockade of the platelet glycoprotein IIb/IIIa receptor with abciximab (

181 Inhibition of the platelet glycoprotein IIb/IIIa receptor with abciximab,

182 Blockade of the platelet glycoprotein IIb/IIIa receptor with the monoclo

183 Inhibition of the platelet glycoprotein IIb/IIIa receptor with the monoclo

184 l antibody Fab fragment directed against the platelet glycoprotein IIb/IIIa receptor, has reduced abr

185 ravenous administration of agents that block platelet glycoprotein IIb/IIIa receptors in the setting

186 ibatide, a cyclic heptapeptide antagonist of platelet glycoprotein IIb/IIIa, are substantially altere

187 e, and lamifiban are new agents that inhibit platelet glycoprotein IIb/IIIa, which serves as the fina

188 rt-acting inhibitor of fibrinogen binding to platelet glycoprotein IIb/IIIa.

189 Thermal denaturation of platelet glycoprotein IIbIIIa (integrin alpha IIb beta 3

190 C resistance and the effect of aspirin and a platelet glycoprotein IIbIIIa antagonist (GR144053F) on

191 8 polymorphism and the Pl(A) polymorphism of platelet glycoprotein IIIa are reported to be independen

192 ociation of the fibrinogen Bbeta 448 and the platelet glycoprotein IIIa Pl(A) polymorphisms in relati

193 The platelet glycoprotein IIIa Pl(A2) polymorphism and the f

194 The gene encoding the platelet glycoprotein IIIa receptor (GPIIIa), shows poly

195 t data suggest that the Pl(A2) allele of the platelet glycoprotein IIIa receptor may be a genetic ris

196 ggregation via competitive interactions with platelet glycoprotein integrin receptor GPIIb/IIIa.

197 dent antibodies (DDAbs) that bind tightly to platelet glycoproteins only when drug is present.

198 Platelet glycoprotein polymorphisms should be added to t

199 helium relies on the interaction between the platelet glycoprotein receptor Ib alpha (GPIb(alpha)) an

200 ation of reversible tether bonds between the platelet glycoprotein receptor Ibalpha and the A1 domain

201 e detected antiplatelet antibodies targeting platelet glycoprotein receptors in 30% of patients with

202 In this study we show that two platelet glycoprotein receptors that signal via an immun

203 The clustering of platelet glycoprotein receptors with cytosolic YxxL and

204 nalysis suggested a link between the VLR and platelet glycoprotein receptors.

205 Platelet glycoprotein VI (GPVI) interacts with collagen

206 Platelet glycoprotein VI (GPVI) is a key receptor for co

207 nvestigated whether TULA-2 has a key role in platelet glycoprotein VI (GPVI) signaling.

208 roup box 1 (HMGB1) protein, but not membrane platelet glycoprotein VI (GPVI), with dependence on extr

209 In this study, we used a (64)Cu-radiolabeled platelet glycoprotein VI fusion protein ((64)Cu-GPVI-Fc)

210 PDE levels of PDGF-AA, platelet glycoprotein VI, integrin-linked kinase-1, high

211 ntibody fragment that inhibits the action of platelet glycoprotein VI.

212 reas PDEs had significantly higher levels of platelet glycoprotein VI.

213 promote tight binding of these antibodies to platelet glycoproteins without linking covalently to pro